DAY 1

DEFINE FLAIR and IFR SWEDEHEART: Safety in Revascularization Based on FFR and iFR in Both Stable and ACS Patients

The safety of physiology-based coronary revascularisation has been supported by evidence for years now. DEFER (1998-2001) was...

DESSOLVE III: Xience vs. MiStent

The MiStent device is made of cobalt-chromium, with struts of up to 64 µm thick. It is coated...

REPRISE III: Lotus and CoreValve Compared in High-Risk or Inoperable Patients

The efficacy of transcatheter aortic valve replacement (TAVR) has been well-established. However, its limitations include suboptimal deployment...

TOPIC: Benefits of Switching Dual Antiplatelet Therapy in Patients with ACS

Newer P2Y12 blockers are the front-line treatment and dual antiplatelet therapy is indicated for 1 year after acute...